Los Angeles Capital Management LLC Has $807,000 Holdings in Bioventus Inc. $BVS

Los Angeles Capital Management LLC boosted its position in shares of Bioventus Inc. (NYSE:BVS) by 23.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 121,835 shares of the company’s stock after buying an additional 22,915 shares during the period. Los Angeles Capital Management LLC’s holdings in Bioventus were worth $807,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after buying an additional 1,538 shares in the last quarter. EntryPoint Capital LLC increased its stake in Bioventus by 7.8% in the first quarter. EntryPoint Capital LLC now owns 28,371 shares of the company’s stock valued at $260,000 after acquiring an additional 2,048 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Bioventus by 12.0% in the second quarter. Harbor Capital Advisors Inc. now owns 24,482 shares of the company’s stock valued at $162,000 after acquiring an additional 2,615 shares during the last quarter. EP Wealth Advisors LLC raised its position in Bioventus by 24.1% during the first quarter. EP Wealth Advisors LLC now owns 17,490 shares of the company’s stock valued at $160,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Bioventus by 35.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after purchasing an additional 4,513 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Trading Down 1.0%

Shares of BVS stock opened at $7.57 on Friday. Bioventus Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $12.61. The stock’s fifty day moving average price is $6.98 and its two-hundred day moving average price is $6.88. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a market cap of $625.88 million, a PE ratio of -12.41 and a beta of 0.80.

Insiders Place Their Bets

In other Bioventus news, Director Michelle Mcmurry-Heath sold 17,701 shares of Bioventus stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $7.42, for a total value of $131,341.42. Following the transaction, the director owned 56,997 shares in the company, valued at $422,917.74. The trade was a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 33.00% of the stock is owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.